Christopher A. Nicita

Mr. Nicita specializes in market and technology assessment, new product planning, and pricing and reimbursement strategy. His business experience, combined with his background in molecular biology research, enables him to understand the scientific and clinical sides of new medical technologies, as well as their commercial potential. He has over 20 years of experience in health care market analysis and medical research.

Mr. Nicita has helped identify and evaluate opportunities afforded by dozens of new products, technologies, and markets and has helped the firm’s clients develop and launch a number of innovative new therapies. He has worked with a range of companies, from industry leaders to start-ups, to make sound portfolio investment decisions and to optimize clinical development strategy. Mr. Nicita frequently consults to companies on prospective in-licensing and merger and acquisition candidates, and has provided due diligence services to a variety of health care investors. He has broad expertise in most therapeutic classes and disease areas including oncology, infectious diseases, immune-mediated and inflammatory diseases, endocrinologic diseases, ultra rare genetic diseases, and cardiovascular diseases, among others.

Mr. Nicita holds a Masters of Business Administration and an Honors Bachelor of Science in Molecular Biology, both from the University of Michigan.